Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

NCT02101268 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

156

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis (PMF)
Post-polycythemia Vera (Post-PV)
Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Interventions

DRUG: Momelotinib
DRUG: Best Available Therapy (BAT)

Sponsor

Sierra Oncology LLC - a GSK company